LENVALIEVA 4 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It inhibits multiple receptors involved in tumor growth and angiogenesis, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, thereby suppressing tumor vascularization and proliferation.

Lenvatinib is used in the treatment of:

1. Differentiated Thyroid Cancer (DTC)
     – Radioiodine-refractory cases

2. Hepatocellular Carcinoma (HCC)
     – First-line therapy in unresectable disease

3. Renal Cell Carcinoma (RCC)
     – In combination with Everolimus (after prior VEGF therapy)

4. Endometrial Carcinoma
     – In combination with Pembrolizumab for advanced disease

Common side effects:

•  Hypertension

•  Diarrhea

•  Fatigue

•  Decreased appetite, weight loss

•  Nausea, vomiting

Serious side effects:

•  Severe hypertension

•  Proteinuria

•  Cardiac dysfunction

•  Hepatotoxicity

•  Gastrointestinal perforation (rare)

Blood pressure, urine protein, and liver function monitoring are essential.

Dosage depends on indication, body weight, and tolerability.

Common adult doses:

•   Thyroid cancer: 24 mg once daily

•   Hepatocellular carcinoma:
   – ≥60 kg: 12 mg once daily
   – <60 kg: 8 mg once daily

•   RCC / Endometrial cancer (with combination therapy): 18–20 mg once daily

4 mg capsules are mainly used for dose adjustment and titration.


NOTE: This medicine should be taken only under a doctor’s supervision.